Breaking News Instant updates and real-time market news.

EPZM

Epizyme

18:47
04/09/18
04/09
18:47
04/09/18
18:47

Epizyme publishes Phase 1 Tazemetostat study in The Lancet Oncology

Epizym announced its first-in-human data on the effects of EZH2 inhibition in patients with advanced solid tumors and B-cell non-Hodgkin lymphoma was published in the peer-reviewed The Lancet Oncology. The objectives of the Phase 1 dose-escalation portion of the study were to evaluate the safety and tolerability of orally dosed tazemetostat, a first-in-class selective inhibitor of EZH2. The study established the recommended dose for the Phase 2 expansion study and demonstrated favorable safety findings and anti-tumor activity. The open-label Phase 1 study was designed to evaluate the maximally tolerated dose and supported defining the recommended Phase 2 dose of tazemetostat. Tazemetostat was dosed twice daily as a single agent in patients with relapsed or refractory B-cell NHL or with advanced solid tumors including molecularly defined INI1- or SMARCA4-negative tumors. Additional study objectives were to evaluate the adverse events, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of the agent. The results of the safety, PK and PD analyses helped determine the RP2D of 800 mg twice daily. The most common treatment-related adverse events, regardless of attribution, were grade 1 or 2 asthenia, anorexia, anemia, muscle spasms, nausea and vomiting. One single dose-limiting toxicity of grade 4 thrombocytopenia was identified at the highest dose of 1600 mg, but no other grade 3 or 4 toxicities were observed at a frequency greater than 5%.

  • 25

    Apr

EPZM Epizyme

03/14/18
RHCO
03/14/18
NO CHANGE
Target $27
RHCO
Buy
Epizyme price target raised to $27 from $21 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Epizyme to $27, saying the company's Q4 earnings call reiterated expectations of on-track data flow in epithelioid sarcoma registrations / NDA filing later this year, the combo data for DLBCL, and the follicular lymphoma data and registration path in the second half of 2018. Lawson keeps his Buy rating and attributes his price target revision to the treatment's higher probability of success.
02/01/18
02/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Roth Capital. 2. Take-Two (TTWO) initiated with an Overweight at Morgan Stanley. 3. AMERI Holdings (AMRH) initiated with an Outperform at Northland. 4. Simply Good Foods (SMPl) initiated with a Buy at SunTrust. 5. Zynerba (ZYNE) assumed with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/01/18
ROTH
02/01/18
INITIATION
Target $24
ROTH
Buy
Epizyme initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Epizyme with a Buy rating and $24 price target as he believes its lead agent tazemetostat, an inhibitor of the histone methyltrasferase EZH2, has laid out a sufficiently wide clinical footprint, and is sufficiently close to an NDA in several indications, that even his conservative approach of ranking its clinical programs shows that the company still remains undervalued.
01/24/18
JEFF
01/24/18
INITIATION
Target $25
JEFF
Buy
Epizyme assumed with a Buy at Jefferies
Jefferies analyst Michael Yee assumed coverage of Epizyme with a Buy rating and raised his price target for the shares to $25 from $23. The company represents an "attractive smid-cap cancer play" with lead drug tazemetostat having activity across a broad range of tumors, Yee tells investors in a research note.

TODAY'S FREE FLY STORIES

ETH

Ethan Allen

$19.04

-0.315 (-1.63%)

14:34
11/15/18
11/15
14:34
11/15/18
14:34
Hot Stocks
Ethan Allen design center set to open in the Superior Marketplace »

Ethan Allen has relocated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZIOP

Ziopharm

$2.95

0.27 (10.07%)

14:31
11/15/18
11/15
14:31
11/15/18
14:31
Upgrade
Ziopharm rating change  »

Ziopharm upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$56.36

0.06 (0.11%)

14:31
11/15/18
11/15
14:31
11/15/18
14:31
Technical Analysis
Technical Take: Papa John's spikes in last 5 minutes »

The shares have spiked to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

WFC

Wells Fargo

$52.69

0.54 (1.04%)

14:28
11/15/18
11/15
14:28
11/15/18
14:28
Periodicals
Wells Fargo to slash roughly 1,000 jobs in U.S., Reuters reports »

Wells Fargo said that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

CCO

Clear Channel Outdoor

$5.49

0.17 (3.20%)

, IHRT

iHeartMedia

$0.00

(0.00%)

14:27
11/15/18
11/15
14:27
11/15/18
14:27
Recommendations
Clear Channel Outdoor, iHeartMedia analyst commentary  »

Barrington says Clear…

CCO

Clear Channel Outdoor

$5.49

0.17 (3.20%)

IHRT

iHeartMedia

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$13.26

-0.36 (-2.64%)

14:20
11/15/18
11/15
14:20
11/15/18
14:20
Options
Large option blocks in Bed, Bath and Beyond as shares reach 52-week lows »

Large option blocks in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
11/15/18
11/15
14:20
11/15/18
14:20
General news
Canada manufacturing preview »

Canada manufacturing…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/15/18
11/15
14:17
11/15/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/15/18
11/15
14:16
11/15/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$64.19

0.69 (1.09%)

14:08
11/15/18
11/15
14:08
11/15/18
14:08
Hot Stocks
Citi reports October credit loss 2.63% vs. 2.42% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

DPZ

Domino's Pizza

14:04
11/15/18
11/15
14:04
11/15/18
14:04
Recommendations
Domino's Pizza analyst commentary  »

Stephens says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

ZIOP

Ziopharm

$2.85

0.17 (6.34%)

14:04
11/15/18
11/15
14:04
11/15/18
14:04
Upgrade
Ziopharm rating change  »

Ziopharm upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$129.48

0.715 (0.56%)

14:02
11/15/18
11/15
14:02
11/15/18
14:02
Hot Stocks
Motorola Solutions boosts quarterly dividend by 10% to 57c »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

FB

Facebook

$143.17

-1.08 (-0.75%)

13:58
11/15/18
11/15
13:58
11/15/18
13:58
Hot Stocks
Facebook board admits to pushing CEO, COO to 'move faster' on interference »

The board of Facebook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SPY

SPDR S&P 500 ETF Trust

$271.90

1.71 (0.63%)

, SPX

S&P 500

$0.00

(0.00%)

13:57
11/15/18
11/15
13:57
11/15/18
13:57
Periodicals
U.S., China step up effort to strike G20 truce on trade, FT reports »

The U.S. and China have…

SPY

SPDR S&P 500 ETF Trust

$271.90

1.71 (0.63%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
11/15/18
11/15
13:55
11/15/18
13:55
General news
U.S. equities snapped back into the green »

U.S. equities snapped…

IAC

IAC

$180.83

0.23 (0.13%)

13:50
11/15/18
11/15
13:50
11/15/18
13:50
Hot Stocks
Rock Holdings acquires Dictionary.com, Thesaurus.com from IAC »

Dan Gilbert's Rock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$46.20

1.49 (3.33%)

13:48
11/15/18
11/15
13:48
11/15/18
13:48
Conference/Events
Fluor to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

RCMT

RCM Technologies

$4.03

0.03 (0.75%)

13:48
11/15/18
11/15
13:48
11/15/18
13:48
Hot Stocks
RCM Technologies announces acquisition of Thermal Kinetics, terms not disclosed »

RCM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARE

Ultragenyx

$51.33

2.92 (6.03%)

13:45
11/15/18
11/15
13:45
11/15/18
13:45
Conference/Events
Ultragenyx haqs a conference call hosted by JPMorgan »

JPMorgan Analyst Kasimov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

  • 27

    Nov

VIAB

Viacom

$31.87

0.07 (0.22%)

, VIA

Viacom

$35.23

-0.1 (-0.28%)

13:41
11/15/18
11/15
13:41
11/15/18
13:41
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VIAB

Viacom

$31.87

0.07 (0.22%)

VIA

Viacom

$35.23

-0.1 (-0.28%)

HP

Helmerich & Payne

$59.45

1.15 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 16

    Nov

  • 16

    Nov

  • 04

    Dec

NVDA

Nvidia

$201.85

4.63 (2.35%)

, AMAT

Applied Materials

$34.94

1.35 (4.02%)

13:41
11/15/18
11/15
13:41
11/15/18
13:41
Earnings
Notable companies reporting after market close »

Notable companies…

NVDA

Nvidia

$201.85

4.63 (2.35%)

AMAT

Applied Materials

$34.94

1.35 (4.02%)

POST

Post Holdings

$91.15

-0.43 (-0.47%)

WSM

Williams-Sonoma

$60.67

-1.09 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

PPL

PPL Corp.

$30.56

-1.63 (-5.06%)

13:35
11/15/18
11/15
13:35
11/15/18
13:35
Options
PPL Corp. put volume heavy and directionally bearish »

Bearish flow noted in PPL…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$19.07

-6.59 (-25.68%)

13:32
11/15/18
11/15
13:32
11/15/18
13:32
Recommendations
PG&E analyst commentary  »

PG&E recent weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$25.48

-0.53 (-2.04%)

13:20
11/15/18
11/15
13:20
11/15/18
13:20
Hot Stocks
MSG Networks announces sponsorship deal for Devils broadcasts with William Hill »

MSG Networks and William…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.